Radiopharm Theranostics (RADX) Competitors $7.05 +0.05 (+0.71%) As of 02:21 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsOwnershipSEC FilingsShort InterestTrendsBuy This Stock RADX vs. BDTX, SCLX, KYTX, AARD, TVGN, CLLS, VTYX, CRBU, CLYM, and SGMOShould you be buying Radiopharm Theranostics stock or one of its competitors? The main competitors of Radiopharm Theranostics include Black Diamond Therapeutics (BDTX), Scilex (SCLX), Kyverna Therapeutics (KYTX), Aardvark Therapeutics (AARD), Tevogen Bio (TVGN), Cellectis (CLLS), Ventyx Biosciences (VTYX), Caribou Biosciences (CRBU), Climb Bio (CLYM), and Sangamo Therapeutics (SGMO). These companies are all part of the "med - biomed/gene" industry. Radiopharm Theranostics vs. Its Competitors Black Diamond Therapeutics Scilex Kyverna Therapeutics Aardvark Therapeutics Tevogen Bio Cellectis Ventyx Biosciences Caribou Biosciences Climb Bio Sangamo Therapeutics Black Diamond Therapeutics (NASDAQ:BDTX) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk. Do insiders and institutionals hold more shares of BDTX or RADX? 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 6.0% of Black Diamond Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has preferable valuation & earnings, BDTX or RADX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBlack Diamond TherapeuticsN/AN/A-$69.68M$0.2313.98Radiopharm TheranosticsN/AN/AN/AN/AN/A Does the media prefer BDTX or RADX? In the previous week, Black Diamond Therapeutics had 1 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 3 mentions for Black Diamond Therapeutics and 2 mentions for Radiopharm Theranostics. Black Diamond Therapeutics' average media sentiment score of 1.07 beat Radiopharm Theranostics' score of 0.95 indicating that Black Diamond Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Black Diamond Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Radiopharm Theranostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is BDTX or RADX more profitable? Black Diamond Therapeutics' return on equity of 12.70% beat Radiopharm Theranostics' return on equity.Company Net Margins Return on Equity Return on Assets Black Diamond TherapeuticsN/A 12.70% 9.58% Radiopharm Theranostics N/A N/A N/A Do analysts rate BDTX or RADX? Black Diamond Therapeutics presently has a consensus price target of $11.67, suggesting a potential upside of 262.88%. Radiopharm Theranostics has a consensus price target of $15.00, suggesting a potential upside of 112.77%. Given Black Diamond Therapeutics' higher probable upside, equities research analysts plainly believe Black Diamond Therapeutics is more favorable than Radiopharm Theranostics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Black Diamond Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Radiopharm Theranostics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.67 SummaryBlack Diamond Therapeutics beats Radiopharm Theranostics on 8 of the 10 factors compared between the two stocks. Get Radiopharm Theranostics News Delivered to You Automatically Sign up to receive the latest news and ratings for RADX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RADX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RADX vs. The Competition Export to ExcelMetricRadiopharm TheranosticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$55.55M$3.14B$5.75B$10.26BDividend YieldN/A2.36%5.88%4.63%P/E RatioN/A21.3577.0126.57Price / SalesN/A458.94528.65122.51Price / CashN/A45.4037.2060.49Price / BookN/A9.6813.966.34Net IncomeN/A-$53.02M$3.29B$270.99M7 Day Performance21.55%1.58%1.38%2.67%1 Month Performance44.17%5.20%5.13%7.23%1 Year PerformanceN/A9.53%84.67%27.97% Radiopharm Theranostics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RADXRadiopharm TheranosticsN/A$7.05+0.7%$15.00+112.8%N/A$55.55MN/A0.00N/ABDTXBlack Diamond Therapeutics3.6488 of 5 stars$3.37+5.0%$11.67+246.2%-41.5%$182.76MN/A14.6590Positive NewsSCLXScilex2.2143 of 5 stars$25.36-0.2%$455.00+1,694.2%-40.9%$176.85M$56.59M-0.8780Positive NewsKYTXKyverna Therapeutics2.4266 of 5 stars$4.15+3.2%$16.60+300.0%-43.8%$173.85M$7.03M-1.1396Gap UpAARDAardvark Therapeutics3.7128 of 5 stars$7.79-2.6%$32.60+318.5%N/A$173.57MN/A0.0018Positive NewsHigh Trading VolumeTVGNTevogen Bio2.5067 of 5 stars$0.88+1.3%$10.00+1,031.6%+85.8%$171.62MN/A0.003CLLSCellectis3.386 of 5 stars$2.98-2.3%$4.00+34.2%+37.4%$169.53M$49.22M-3.63290News CoverageShort Interest ↓High Trading VolumeVTYXVentyx Biosciences2.5903 of 5 stars$2.38+0.4%$7.50+215.1%-0.4%$169MN/A-1.4230Positive NewsCRBUCaribou Biosciences2.8643 of 5 stars$1.91+7.3%$6.67+249.0%-11.3%$165.76M$9.99M-1.07100Positive NewsCLYMClimb Bio3.7804 of 5 stars$2.40+0.8%$9.00+275.0%N/A$161.28MN/A-3.439Positive NewsSGMOSangamo Therapeutics2.8458 of 5 stars$0.53flat$4.50+746.2%-38.7%$160.45M$57.80M-1.83480Positive News Related Companies and Tools Related Companies BDTX Competitors SCLX Competitors KYTX Competitors AARD Competitors TVGN Competitors CLLS Competitors VTYX Competitors CRBU Competitors CLYM Competitors SGMO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RADX) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Radiopharm Theranostics Limited - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Radiopharm Theranostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
